Our 5-Methylcytidine Modification Service boosts therapeutic efficacy and transcript stability via precision epitranscriptomic engineering. Strategic m5C incorporation modifies RNA structure for superior translation and immune evasion, elevating mRNA performance for next-gen vaccines and therapeutics.
Creative Biolabs' m5C expertise solves mRNA therapy challenges, maximizing protein expression duration/quantity while reducing adverse immune responses, delivering optimized transcripts to accelerate your project.
Discover How We Can Help - Request a Consultation
m5C refers to the addition of a methyl group (CH3) to the C-5 position of the cytosine ring. This seemingly small chemical addition yields profound functional changes. Mechanistically, m5C substitution stabilizes the RNA helix by promoting favorable base stacking and increasing the thermal stability of hydrogen bonds. This superior structural integrity ensures the mRNA resists cleavage and maintains its active conformation longer within the cytoplasm, ready for repeated ribosomal translation.
Fig.1 RNA m5C modification plays a crucial role in various biological processes.1
The strategic use of m5C is transforming several high-value therapeutic areas:
Our robust, multi-stage workflow is designed for transparency and efficiency, ensuring high-quality, clinical-ready deliverables.
| Stage | Activity Involved |
|---|---|
| Required Starting Materials | Target mRNA sequence/plasmid, desired modification sites or target region, target cell type/therapeutic application (e.g., vaccine, protein replacement). |
| Project Intake & Design | Comprehensive review of client-provided materials and rational design of the epitranscriptomic strategy, including m5C concentration optimization. |
| Custom Nucleotide Synthesis & Prep | Large-scale, high-purity synthesis and purification of m5C nucleotides and other necessary components (e.g., Cap analogues). |
| IVT & Modification Integration | Optimized in vitro transcription reaction incorporating the m5C nucleotides to produce the full-length therapeutic mRNA. |
| Final Purification & QC | Multi-step purification (e.g., HPLC-based) to remove contaminants and comprehensive quality control, including capping efficiency and impurity analysis. |
Final Deliverables:
Estimated Timeframe: The typical timeframe for this service ranges from 4 to 8 weeks, depending on the complexity of the target sequence, the inclusion of combinatorial modifications (Ψ, m6A), and the required batch size.
Our Advantage
Custom Epitranscriptomic Design
Comprehensive, rational m5C modification strategy (concentration, placement) fully customized to your therapeutic target and required translational output.
Maximized In Vivo Longevity
Precision m5C incorporation induces favorable base stacking, delivering transcripts with better structural stability and longer therapeutic half-life than conventional mRNA.
Advanced Immune Evasion
Strategic modification helps transcripts evade innate immune sensors (e.g., TLRs), ensuring low systemic inflammation and prolonged protein expression—key for sensitive applications like in vivo cell reprogramming.
Integrated GMP/GLP Manufacturing
One-stop service for high-purity custom m5C nucleoside synthesis and large-scale, clinical-grade m5C-modified mRNA production to speed up IND filing.
Proprietary Analytical Tools
Advanced QC (bisulfite sequencing, mass spectrometry) maps and quantifies m5C sites, ensuring top-tier translational fidelity and product consistency.
End-to-End Delivery Solutions
Seamless integration of m5C expertise with Creative Biolabs' optimized LNP formulation services, offering a complete solution from sequence to targeted delivery.
A: Ψ excels at immune evasion, while m5C boosts structural stability and translation fidelity via unique base-stacking. Combining them creates synergy, optimizing immune stealth and protein output. Consult us for a tailored combinatorial strategy.
A: We use proprietary IVT protocols for high-efficiency incorporation. Final QC uses bisulfite sequencing and mass spectrometry to confirm m5C presence, distribution, and transcript integrity.
A: m5C works universally but shines in interferon-sensitive cells (e.g., dendritic cells, macrophages)—key for cancer immunotherapy/vaccines—significantly boosting translational yield in these targets.
A: We offer end-to-end epitranscriptomic engineering (rational design, proprietary synthesis, integrated QC/delivery) vs. just reagents. Over 20 years of expertise ensure a higher-performing final product.
Creative Biolabs' 5-Methylcytidine Modification Service is your essential tool for advancing next-generation mRNA therapeutics. We combine deep scientific expertise with a detailed, high-quality workflow to deliver modified transcripts with maximized stability, reduced immunogenicity, and superior translational efficiency.
Contact Our Team for More Information and to Discuss Your Project| Cat. No | Product Name | Promoter |
|---|---|---|
| CAT#: GTVCR-WQ001MR | IVTScrip™ pT7-mRNA-EGFP Vector | T7 |
| CAT#: GTVCR-WQ002MR | IVTScrip™ pT7-VEE-mRNA-EGFP Vector | T7 |
| CAT#: GTVCR-WQ003MR | IVTScrip™ pT7-VEE-mRNA-FLuc Vector | T7 |
| CAT#: GTVCR-WQ87MR | IVTScrip™ pT7-VEE-mRNA-Anti-SELP, 42-89-glycoprotein Vector | T7 |
| Cat. No | Product Name | Type |
|---|---|---|
| CAT#: GTTS-WQ001MR) | IVTScrip™ mRNA-EGFP (Cap 1, 30 nt-poly(A)) | Reporter Gene |
| CAT#: GTTS-WK18036MR | IVTScrip™ mRNA-Human AIMP2, (Cap 1, Pseudo-UTP, 120 nt-poly(A)) | Enzyme mRNA |
| (CAT#: GTTS-WQ004MR) | IVTScrip™ mRNA-Fluc (Cap 1, 30 nt-poly(A)) | Reporter Gene |
| (CAT#: GTTS-WQ009MR) | IVTScrip™ mRNA-β gal (Cap 1, 30 nt-poly(A)) | Reporter Gene |
Reference
